Search results

Families have marked the seventh anniversary of the legalisation of medical cannabis in the UK with further calls for urgent government action on NHS access. Dozens of families attended Westminster on Tuesday (4 November) to meet with cross-party MPs and demand immediate action to address the...

The endocannabinoid system (ECS) helps regulate vital bodily functions from mood and pain to immune response, yet it remains one of medicine’s best-kept secrets. We unpack the science behind the ECS and its significance in a range of chronic conditions. The endocannabinoid system (ECS) plays a...

Zurich’s flagship adult-use cannabis trial, Züri Can, could now run until 2028 after city officials applied this week to extend the project by two years, citing strong early results in reducing illicit sales and promoting safer consumption. The move comes as the Swiss Federal Government...

Healthcare professionals attending the Cannabis Health Symposium next month will be able to earn CPD points to support their professional development. The Cannabis Health Symposium is a Continuing Professional Development (CPD)-accredited event, meaning attendees can earn professional...

In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field of medicine, taking readers inside the clinic and offering a doctor’s perspective on what it really...

Almost seven years since medical cannabis was legalised in the UK on 1st November 2018, less than 1% of the UK’s approximate 100,000 doctors on the General Medical Council (GMC) Specialist Register have the training required to prescribe medical cannabis. While the UK’s medical cannabis market...

A growing number of patients are now prescribed medical cannabis for common mental health issues and neurodiverse conditions, such as autism and ADHD. Ahead of Cannabis Health Symposium next month, we examine the research and real-world evidence behind the use of cannabis-based medicines in...

Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London. The event, delivered in partnership with the Medical Cannabis Clinicians Society (MCCS), will focus on strengthening clinical...

The Advisory Council on the Misuse of Drugs (ACMD) has closed its latest call for evidence into the impact of medical cannabis legalisation, in what will mark the most comprehensive review of the UK’s cannabis-based products for medicinal use (CBPM) framework since it was introduced in 2018...

How one oncologist is helping redefine patient care and the future of integrated healthcare. Medical cannabis is starting to have a very different kind of conversation in the UK. From mainstream voices like Rory Cellan-Jones exploring patient experiences on his Movers & Shakers podcast, to...

German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval. After seven years of endeavour, and an investment of over $250m, its VER-01 chronic pain-relief drug has passed a Phase 3 trial in its home...

As the prevalence of dementia and other neurodegenerative conditions continues to rise globally, there is growing interest in the role of cannabis-based medicines in symptom management. A small number of studies, combined with real-world clinical experience is beginning to provide important...

Medical cannabis patients will host a major educational event in the UK next month, aiming to bridge the gap between patients and healthcare professionals through evidence, empathy and lived experience. The international patient-led organisation We, The Patients, will bring its educational...

Experts say real-world evidence could offer crucial insights into how these medicines work in practice, and help widen access for patients. For the last 50 years, randomised controlled trials (RCTs) have been considered the ‘gold standard’ research methodology for measuring the safety and...

In a historic move, Spain’s Council of Ministers has approved a long-awaited Royal Decree regulating the medicinal use of cannabis preparations in hospital settings. Following years of advocacy on behalf of patients and campaigners, the decision marks a decisive step toward the integration of...

Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory. As the landmark CanG Act approaches its second year, it has become a highly charged and increasingly divisive issue politically...

Dr Sue Clenton, Medical Director of Releaf cannabis clinic explains what it takes to go from a few hundred to thousands of patients, without compromising on the quality of care. When people talk about growth in healthcare, the conversation often centres on numbers – the number of patients...

New guidelines around THC levels, dosages, and eligibility, aim to bring more clarity and consistency to the practice of prescribing cannabis-based medicines in the UK. Almost seven years since medical cannabis was legalised in the UK, around 160 specialist consultants are now actively...

Words by Lawrence Purkiss and Sarah Sinclair Portugal hosted its seventh international conference on medical cannabis (PTMC) in central Lisbon last week, amid a growing feeling that the country – a once-thriving hub for European cannabis exports – is at an inflection point. Discussion among...

By Rupa Shah, Head of Compliance at Releaf The conversation around workers’ rights and medical cannabis is still at a very early stage in the UK. Despite the fact that thousands of patients now access cannabis-based medicines legally through prescription, the framework remains poorly...